Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
SAN DIEGO , Jan. 7, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO ® ), in Mirati's planned Phase
View HTML
Toggle Summary Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 2, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 th at 8:00 a.m. PST / 11:00 a.m. EST . Charles M.
View HTML
Toggle Summary Mirati Therapeutics Added To NASDAQ Biotechnology Index
SAN DIEGO , Dec. 20, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq: ^NBI). The Company's addition to the Index will become effective prior
View HTML
Toggle Summary Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO , Dec. 10, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately. Ms. Martinez-Davis is the President of BioPharma Latin
View HTML
Toggle Summary Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
SAN DIEGO , Nov. 29, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that the U.S. Food and Drug Administration ( FDA ) has cleared the company's investigational new drug (IND) application for MRTX849, a small molecule
View HTML
Toggle Summary Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 20, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27 th at 12:30 p.m. EST / 9:30 a.m. PST .
View HTML
Toggle Summary Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
SAN DIEGO , Nov. 9, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO ® ) in non-small cell lung cancer
View HTML
Toggle Summary Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO , Nov. 9, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI ® ) in non-small cell lung cancer (NSCLC) patients at the
View HTML
Toggle Summary Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
SAN DIEGO , Nov. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in a Phase 1b clinical trial to assess the
View HTML
Toggle Summary Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14 th at 1:40 p.m. MST / 12:40 p.m. PST . Charles M.
View HTML